Rural china tests smart wearables to stop heart failure before it starts

NCT ID NCT07492498

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a telemedicine program, led by village doctors and supported by wearable devices and remote specialists, can prevent heart failure in older adults (65-80) with atrial fibrillation living in rural China. About 1,268 participants will be assigned to either standard care or the digital program, which includes daily health monitoring, lifestyle coaching, and optimized medication plans. Researchers will track heart health scores, major cardiovascular events, and signs of early heart dysfunction over up to 4 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Telemedicine-based integrated care model (village doctor-led, IoT platform, wearables, remote specialist consults)

What this could lead to

If successful, this could show that a simple, tech-supported care model can prevent heart failure in high-risk older adults, especially in rural areas with limited access to specialists.

What could go wrong

This is a large trial but hasn't started yet. Results depend on real-world adherence and technology use in rural settings, which may be challenging. It's not testing a new drug, so the impact may be modest.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation cardiovascular disorder heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.